Reprogramming and multi-lineage transdifferentiation attenuate the tumorigenicity of colorectal cancer cells

Area of Science:

• Stem cell biology
• Cancer research
• Epigenetics

Background:

• Reprogramming somatic cells into induced pluripotent stem cells (iPSCs) and transdifferentiation are advanced techniques.
• These methods hold potential for cancer therapy by switching malignant phenotypes to benign ones.
• Limited research exists on reprogramming cancer cells to reduce malignancy.

Purpose of the Study:

• To investigate the reprogramming of colorectal cancer (CRC) cells into iPSCs.
• To assess the tumorigenesis of reprogrammed CRC cells and their differentiated progeny.
• To explore the potential of multi-lineage differentiation as a therapeutic strategy for CRC.

Main Methods:

• Reprogramming of two CRC cell lines (DLD1, HT29) into iPSCs (D-iPSCs, H-iPSCs).
• Induction of D- and H-iPSCs differentiation into cardiomyocyte, neuron, and adipocyte-like cells.
• In vitro and in vivo assessment of tumorigenesis in reprogrammed and differentiated cells.
• RNA-sequencing (RNA-Seq) analysis to identify epigenetic changes.

Main Results:

• CRC cell lines were successfully reprogrammed into iPSCs with reduced tumorigenesis.
• Differentiated cells from these iPSCs showed further attenuated malignancy in vitro and in vivo.
• RNA-Seq revealed epigenetic modifications correlating with reduced tumorigenicity after reprogramming and differentiation.

Conclusions:

• Colorectal cancer cells can be reprogrammed into iPSCs and subsequently differentiated into various cell types.
• This process significantly attenuates cancer cell malignancy both in vitro and in vivo.
• Multi-lineage differentiation of reprogrammed CRC cells presents a promising therapeutic strategy for colorectal cancer.